ScripRedwood City, CA-based Soleno Therapeutics is firing on all cylinders with the launch of Vykat XR (diazoxide choline), the first drug approved to treat intense and persistent hunger in people with t
ScripIn a year that has so far been marked by major changes and upheaval at the US Food and Drug Administration, pharma companies are largely still on track with their expected 2025 approvals and launches.
Pink SheetThe European Medicines Agency has begun reviewing a new batch of products for potential pan-EU marketing approval, including LIB Therapeutics’ lerodalcibep for treating primary hypercholesterolemia or
ScripStock market turmoil due to macroeconomic uncertainty and biopharmaceutical industry-specific concerns have made it more difficult for publicly traded drug developers to pursue follow-on public offeri